Multiple SclerosisMSNCT07504120

The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis

A study testing Pilates in people with Multiple Sclerosis and Pilates Exercise, run by University of Illinois at Chicago at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Multiple Sclerosis, Pilates Exercise, Walking
What is being tested?: Pilates
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 50 participants
Where: 1 siteUnited States
Study dates: 1 Nov 2025to 1 Dec 2027
Phase: Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age 18 years or older
Self-reported diagnosis of multiple sclerosis by a neurologist
Relapse-free for the past 30 days before screening
Able to speak and read English as the primary language
Access to the internet and e-mail,
Ability to use Zoom, and willingness to complete testing sessions and questionnaires

Show all 11Show fewer

Ambulatory without an assistive device (for example, cane)
Low to moderate disability, defined as a score of 0-4 on the Patient-Determined Disease Steps (PDDS)
Insufficiently active, defined as a score < 14 on the Godin Leisure-Time Exercise Questionnaire-Health Contribution Score (GLTEQ-HCS)
Adequate visual ability and literacy to read materials printed in 14-point font
Currently treated with a disease-modifying therapy

Who cannot join

Pregnant
Elevated risk for strenuous or maximal exercise, defined as more than one "Yes" response on the Physical Activity Readiness Questionnaire (PAR-Q) during screening

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting

University of Illinois Chicago
Chicago, Illinois, 60612
Parisa Najafi, PhD, 7735055923, pems@uic.edu
Recruiting

Other trials in United States

About this study

Official title: Does Remotely Delivered Pilates Influence Physical and Psychological Outcomes in Individuals With Multiple Sclerosis?

Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.

Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Read the detailed description

The current study will determine the feasibility and efficacy of a 16-week remotely delivered Pilates intervention for improving physical and psychological outcomes, and QOL, compared with a control condition, in individuals with MS. This represents a significant step forward in examining Pilates as an accessible, complementary therapy in MS.

Conditions: Multiple Sclerosis, Pilates Exercise, Walking, Balance, Fatigue in Multiple Sclerosis, Pain Management
Being tested: Pilates
Keywords: multiple sclerosis, Pilates, Fatigue, Cognition, Quality of life, Walking, Depression, Balance, Pain
Medical subject headings: Multiple Sclerosis, Agnosia, Depression, Fatigue, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

PilatesBehavioural
REMOTLY PILATES EXERCISE

Study groups in NCT07504120
Study group	Role	What they receive
Pilates group	Other	Behavioral: Pilates group Receives: Behavioral: Pilates
Control group	No intervention	Waitlist Group

What is being measured

The primary outcome is the main question the study is designed to answer.

Change from baseline in walking endurance (Six-Minute Walk Test distance)
Distance walked during the Six-Minute Walk Test (6MWT) will be measured in meters. The outcome is the change from baseline to 16 weeks in 6MWT distance.
Measured: Baseline and 16 weeks (end of treatment)
Change from baseline in walking speed (Timed 25-Foot Walk)
Walking speed will be assessed using the Timed 25-Foot Walk (T25FW). The outcome is the change from baseline to 16 weeks in time to walk 25 feet, measured in seconds.
Measured: Baseline and 16 weeks (end of treatment)
Change from baseline in balance (Berg Balance Scale)
Balance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure of static and dynamic balance. Each item is scored from 0 to 4, and the outcome will be the change from baseline to 16 weeks in the BBS total score (range 0-56), with higher scores indicating better balance and lower risk of falls.
Measured: Baseline and 16 weeks (end of treatment)
Change from baseline in fatigue (Fatigue Severity Scale)
Fatigue will be measured using the Fatigue Severity Scale (FSS), a 9-item questionnaire assessing the impact of fatigue on daily functioning. Each item is rated from 1 to 7, and the outcome will be the change from baseline to 16 weeks in the FSS mean score (range 1-7), with higher scores indicating more severe fatigue.
Measured: Baseline and 16 weeks (end of treatment)
Change from baseline in pain (Short-form McGill Pain Questionnaire)
Pain will be measured using the Short-form McGill Pain Questionnaire (SF-MPQ). The outcome is the change from baseline to 16 weeks in SF-MPQ total score.
Measured: Baseline and 16 weeks (end of treatment)

Secondary outcomes (6)

Change from baseline in cognitive processing speed (Symbol Digit Modalities Test)
Cognitive processing speed will be assessed using the Symbol Digit Modalities Test (SDMT). The outcome is the change from baseline to 16 weeks in SDMT total score, with higher scores indicating better processing speed. SDMT scores typically range from 0 to about 110 correct responses.
Measured: Baseline and 16 weeks (end of treatment)
Change from baseline in verbal learning and memory (California Verbal Learning Test-II)
Verbal learning and memory will be assessed using the California Verbal Learning Test-II (CVLT-II). The outcome is the change from baseline to 16 weeks in CVLT-II total recall score, with higher scores indicating better verbal learning and memory. CVLT-II total recall scores typically range from 0 to about 80.
Measured: Baseline and 16 weeks (end of treatment)
Change from baseline in visuospatial learning and memory (Brief Visuospatial Memory Test-Revised)
Visuospatial learning and memory will be assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). The outcome is the change from baseline to 16 weeks in BVMT-R total recall score, with higher scores indicating better visuospatial memory. BVMT-R total recall scores typically range from 0 to 36.
Measured: Baseline and 16 weeks (end of treatment)
Change from baseline in depression symptoms
Depression will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Depression subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in depression total score, with higher scores indicating greater depressive symptoms. Typical depression scales have ranges such as 0-21 (HADS-D) ; enter the exact range that matches the scale you are using.
Measured: Baseline and 16 weeks (end of treatment)
Change from baseline in anxiety symptoms
Anxiety will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Anxiety subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in anxiety total score, with higher scores indicating greater anxiety. Typical anxiety scales have ranges such as 0-21 (HADS-A) or 0-63 (BAI); enter the exact range that matches the scale you are using.
Measured: Baseline and 16 weeks (end of treatment)
Change from baseline in health-related quality of life
Health-related quality of life will be assessed using a validated questionnaire (e.g., the MSQoL-54 or a comparable instrument). The outcome is the change from baseline to 16 weeks in the quality-of-life total score or composite score. For instruments scored 0-100, higher scores typically indicate better quality of life; specify the exact scoring range and direction according to your chosen measure.
Measured: Baseline and 16 weeks (end of treatment)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Nov 20251 Dec 2027

First posted31 Mar 2026
Study start1 Nov 2025
Primary completion1 Dec 2027 (estimated)
Study completion1 Dec 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Multiple SclerosisStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Other
Allocation: Randomised
Intervention model: Parallel groups
Model description: our participants will be randomly assigned to either the Pilates intervention group or the waitlist control group, and both groups proceed simultaneously-this is a parallel design.
Masking: Single blind
Who is masked: Outcomes assessor
Enrolment: 50 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07504120
Sponsor's protocol ID: STUDY2025-0648-MOD001
Other IDs: MB-2110-38597
Acronym: MS
Status last verified: Oct 2026
First submitted: 2 Oct 2025
Last updated: 6 Oct 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided

Interested in taking part?

Each site lists its own contact. Pick the site nearest to you.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Active, not recruiting
Intravoxel Incoherent Motion (IVIM) Magnetic Resonance Imaging in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
Recruiting
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
Multiple Sclerosis
Active, not recruitingPhase 3
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
Active, not recruiting
Tai Chi Training for Persons With Multiple Sclerosis.
Multiple Sclerosis (MS) - Relapsing-remitting

All Multiple Sclerosis trials